Related Experiment Video

Updated: Nov 30, 2025

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 26, 2014

23.7K

SARS-CoV-2 cell receptor gene ACE2 -mediated immunomodulation in breast cancer subtypes

Vikas Kumar Bhari1, Durgesh Kumar2, Surendra Kumar3

  • 1Department of Biosciences, Manipal University Jaipur, Rajasthan, India.

Biochemistry and Biophysics Reports
|November 12, 2020
PubMed

Insights

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) impacts cancer patients. Angiotensin-converting enzyme 2 (ACE2) plays a role in how SARS-CoV-2 affects immune cells in breast cancer, potentially influencing treatment resistance.

Area of Science:

  • Oncology
  • Virology
  • Immunology

Background:

  • The COVID-19 pandemic, caused by SARS-CoV-2, poses risks to cancer patients due to their compromised immune systems.
  • Angiotensin-converting enzyme 2 (ACE2) is the primary entry point for SARS-CoV-2 into host cells and plays a role in immune modulation.
  • Understanding SARS-CoV-2's impact on cancer immunity is crucial for developing new therapeutic strategies.

Purpose of the Study:

  • To investigate the correlation between ACE2 expression and tumor immune infiltration (TIL) in different breast cancer subtypes.
  • To explore the immunomodulatory role of ACE2 in the context of SARS-CoV-2 infection within breast cancer.

Main Methods:

  • Utilized the TIMER database to analyze ACE2 expression and its association with immune cell infiltration.
  • Examined immune cell type markers across various breast cancer subtypes.
  • Correlated ACE2 levels with tumor immune infiltration and specific immune cell populations.

Main Results:

  • Identified a significant correlation between ACE2 and tumor immune infiltration levels in breast cancer.
  • Revealed an immunomodulatory role for ACE2, particularly in the luminal A breast cancer subtype.
  • ACE2's influence may be linked to therapeutic resistance in luminal A breast cancer.

Conclusions:

  • ACE2 plays a role in modulating the tumor immune microenvironment in breast cancer.
  • The findings suggest ACE2's involvement in therapeutic resistance within the luminal A subtype.
  • Further research into ACE2's function could lead to novel treatments for virus-associated cancers.
Keywords:
ACE2Breast cancerCOVID-19GenomicsImmunomodulation

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.1K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
955
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.3K